Evidence map›Paper›PMID 38332334›Full record

ArticleScientific reports2024

Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'.

Rosalind G McAlpine, George Blackburne, Sunjeev K Kamboj

Registry-linked trialAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07737990 (Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07737990 naenrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

TypeinterventionalSponsorJoshua RosenblatRan2026 to 2030Enrolled65ConditionsTreatment-resistant Depression (TRD)ArmsGroup integration therapy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Traumatic Psychedelic Experiences.Current topics in behavioral neurosciences · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rosalind G McAlpineClinical Psychopharmacology Unit, Clinical, Educational and Health Psychology, University College London, London, UK. rosalind.mcalpine.18@ucl.ac.uk.
George BlackburneClinical Psychopharmacology Unit, Clinical, Educational and Health Psychology, University College London, London, UK.
Sunjeev K KambojClinical Psychopharmacology Unit, Clinical, Educational and Health Psychology, University College London, London, UK.

Funding

Wellcome TrustWellcome Trust (Wellcome) 218497/Z/19/Z
6 · The paper itself

Abstract

Preparing participants for psychedelic experiences is crucial for ensuring these experiences are safe and, potentially beneficial. However, there is currently no validated measure to assess the extent to which participants are well-prepared for such experiences. Our study aimed to address this gap by developing, validating, and testing the Psychedelic Preparedness Scale (PPS). Using a novel iterative Delphi-focus group methodology ('DelFo'), followed by qualitative pre-test interviews, we incorporated the perspectives of expert clinicians/researchers and of psychedelic users to generate items for the scale. Psychometric validation of the PPS was carried out in two large online samples of psychedelic users (N = 516; N = 716), and the scale was also administered to a group of participants before and after a 5-7-day psilocybin retreat (N = 46). Exploratory and confirmatory factor analysis identified four factors from the 20-item PPS: Knowledge-Expectations, Intention-Preparation, Psychophysical-Readiness, and Support-Planning. The PPS demonstrated excellent reliability (ω = 0.954) and evidence supporting convergent, divergent and discriminant validity was also obtained. Significant differences between those scoring high and low (on psychedelic preparedness) before the psychedelic experience were found on measures of mental health/wellbeing outcomes assessed after the experience, suggesting that the scale has predictive utility. By prospectively measuring modifiable pre-treatment preparatory behaviours and attitudes using the PPS, it may be possible to determine whether a participant has generated the appropriate mental 'set' and is therefore likely to benefit from a psychedelic experience, or at least, less likely to be harmed.

Indexed as

HallucinogensHumansPsilocybinPsychometricsReproducibility of ResultsSurveys and QuestionnairesHallucinogensPsilocybin

Identifiers

PMID38332334
PMCPMC10853197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.